TNF Pharmaceuticals Sets Sights On Revolutionary Clinical Trials For Age-Related Decline

TNF Pharmaceuticals, Inc., a biopharmaceutical company in the clinical development phase focused on innovative treatments for age-related disorders, as well as autoimmune and inflammatory conditions, has announced its plans to advance its leading candidate, MYMD-1®, into fully funded mid-stage clinical trials. MYMD-1 is a small molecule designed to inhibit excessive TNF-alpha (TNF-α) activity in the bloodstream, thereby modulating the immuno-metabolic system. The upcoming trials will investigate the drug's effectiveness in treating sarcopenia and frailty, building on promising results from a previous Phase 2 study.

Mitchell Glass, M.D., President and Chief Medical Officer of TNF Pharmaceuticals, said in a statement, “In our view, MYMD-1, if approved, could be the first orally administered TNF-alpha inhibitor drug and the first and only therapy for sarcopenia, a common age-related disorder that causes a prolonged decline in physical function. The success of our clinical strategy and regulatory pathway to date supports MYMD-1’s potential to disrupt the TNF-alpha inhibitor market.”

He further added, “As we prepare for our next fully funded clinical studies in sarcopenia/frailty, we also have open INDs for Phase 2 trials of MYMD-1 in two additional chronic inflammatory conditions, rheumatoid arthritis (RA) and Hashimoto’s thyroiditis, which we could pursue with the support of non-dilutive domestic and/or international development partnerships. A partner outside of the U.S. could potentially help us accelerate the timeline to commercialization of our lead asset.”

He concluded by saying “Each of MYMD-1’s indications provide solid measures of Company value. We are excited about the positive data we have gathered so far for our lead asset. Our next steps, to be revealed soon, will extend our reach toward significant and sustainable value creation, and long-term Company growth.”